所在地を検索
営業時間、予約なし診療およびご予約。Unable to load global navigation.
Synonyms
- ABL1 Mutation Analysis for Resistance to Imatinib Mesylate
- Gleevec Resistance Mutation Analysis
- Imatinib Mesylate Resistance Analysis
Special Instructions
Please direct any questions regarding this test to oncology customer service at 800-345-4363.
Expected Turnaround Time
10 - 14 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Related Documents
Specimen Requirements
Specimen
Whole blood or bone marrow
Volume
3 to 5 mL whole blood or 1 to 2 mL bone marrow
Minimum Volume
3 mL whole blood or 1 mL bone marrow
Container
Lavender-top (EDTA) tube, green-top (sodium heparin) tube, yellow-top (ACD-A) tube, tan-top (K2-EDTA) tube or pink-top (K2-EDTA) tube
Collection
Submit at room temperature. Specimens should arrive in the laboratory within 48 hours of collection. Indicate date and time of collection on request form.
Storage Instructions
Ship at room temperature. If specimen must be stored prior to shipment, store at 2°C to 8°C.
Causes for Rejection
Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; unsuitable specimens include but are not limited to: frozen whole blood or marrow; a leaking tube; clotted blood or marrow; a grossly hemolyzed specimen or otherwise visibly degraded; specimen suspected of being contaminated by another specimen; specimen contains specific foreign material
Test Details
Use
Point mutations within the ABL1 kinase domain of the BCR-ABL1 fusion gene frequently cause secondary resistance to tyrosine kinase inhibitor (TKI) therapy. Those patients with a longer duration of CML prior to initiation of imatinib therapy are reported to have a higher incidence of detectable mutations compared to patients with an earlier onset of imatinib therapy. In addition, failure to achieve a major cytogenetic response within the first six months of therapy often reflects the presence of a mutation or a high probability that a mutation will subsequently be detected. Biochemical and cellular assays have demonstrated that the different BCR-ABL1 kinase domain mutations result in varying levels of resistance. Presence of kinase domain mutations are associated with poor prognosis and higher risk of disease progression. The different mutations may require differing strategies to overcome resistance, such as dose escalation, combination therapy or transplantation. Candidates for the BCR-ABL1 kinase domain mutation analysis include:
• Response milestones not reached
· Any sign of loss of hematologic response
· Any sign of loss of Complete cytogenetic response (CCyR) or its molecular response correlate-defined as an increase in BCR::ABL1 transcript to >1% International scale [IS]
· 1-log increase in BCR::ABL1 transcript levels and loss of Major Molecular Response (MMR)
• Disease progression to Accelerated Phase (AP-CML) or Blast Phase (BP-CML)
This assay sequences the entire ABL1 kinase domain and will detect all mutations in ABL1 kinase recommended by guidelines including G250E, Y253H, E255K/V, V299L, T315I/A, F317L/V/I/C, A337T, F359V/I/C and P465S.
Limitations
In vitro studies indicate that this analysis has a mutation detection sensitivity of ∼20%. Mutations occurring outside of the analyzed region of the ABL kinase domain will also not be detected by this assay.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Polymerase chain reaction (PCR); direct sequencing; capillary electrophoresis
References
Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 2004 Nov 1; 104(9):2926-2932.15256429
Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-Loop) are associated with a poor prognosis. Blood. 2003 Jul 1; 102(1):276-283.12623848
Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol. 2005 Jan; 12(1):33-39.15604889
National Comprehensive Cancer Network (NCCN). NCCN Guidelines: Chronic Myeloid Leukemia. Version 1.2025. NCCN website: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427. Accessed August 2024.
Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIVEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4100-4109.15867198
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 480510 | BCR-ABL1 kinase domain | 55135-8 | 000000 | |||
| 480510 | BCR-ABL1 kinase domain | 480511 | Result: | 55135-8 | ||
| 480510 | BCR-ABL1 kinase domain | 480512 | Nucleotide Change: | 48004-6 | ||
| 480510 | BCR-ABL1 kinase domain | 480513 | Predicted Amino Acid Change: | 48005-3 | ||
| 480510 | BCR-ABL1 kinase domain | 480515 | Director Review: | 72486-4 | ||
| 480510 | BCR-ABL1 kinase domain | 480843 | Interpretation: | 50398-7 | ||
| 480510 | BCR-ABL1 kinase domain | 480844 | Methodology: | 49549-9 | ||
| 480510 | BCR-ABL1 kinase domain | 481526 | Disclaimer: | N/A |
© 2025 Laboratory Corporation of America® Holdings. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf